STOK Stoke Therapeutics Forecast, Technical & Fundamental Analysis
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine... Show more
STOK is expected to report earnings to fall 2.76% to -76 cents per share on August 10
Q2'26
Est.
$-0.77
Q1'26
Beat
by $0.02
Q4'25
Missed
by $0.23
Q3'25
Missed
by $0.07
Q2'25
Beat
by $0.10
The last earnings report on May 07 showed earnings per share of -79 cents, beating the estimate of -81 cents. With 251.26K shares outstanding, the current market capitalization sits at 1.72B.
A.I. Advisor
published General Information
General Information
a company, which engages in the research and development of treatments for genetic diseases.
A.I.dvisor indicates that over the last year, STOK has been loosely correlated with RCKT. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if STOK jumps, then RCKT could also see price increases.
STOK in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 13, 2026
STOK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 30 cases where STOK's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for STOK's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where STOK advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 256 cases where STOK Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on July 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STOK as a result. In of 82 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for STOK turned negative on July 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
STOK moved below its 50-day moving average on July 13, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for STOK crossed bearishly below the 50-day moving average on July 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The 50-day moving average for STOK moved below the 200-day moving average on July 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where STOK declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. STOK’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.365) is normal, around the industry mean (20.520). P/E Ratio (48.338) is within average values for comparable stocks, (37.338). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.489). STOK has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.038). P/S Ratio (52.083) is also within normal values, averaging (396.412).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STOK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
